APLI:CC - InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Enters Acquisition Agreement to Acquire Biodefense Vaccine Developer
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF). Appili is a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. According to the agreement, Adivir Inc., a wholly owned subsidiary of Aditxt, will acquire all issued and outstanding Class A common shares of Appili. Assets acquired by Aditxt will include FDA-approved LIKMEZ(TM), which is the ATI-1701 tularemia vaccine defense program, and the ATI-1801 topical formulation. “The acquisition of Appili would represent another step in Aditxt’s journey towards advancing promising innovations in health,” said Aditxt cofounder, chair and CEO Amro Albanna in the press release. “Our mission is to accelerate some of the most promising health innovations, like those developed by Appili, to reach their full potential and to have a lasting impact. The urgency for innovative and effective public-health solutions is unprecedented. The need to discover and bring new treatments to the market or to enhance existing ones to combat public-health challenges has never been more critical. By integrating Appili’s proven expertise and diverse portfolio in the infectious disease and biodefense domain, Aditxt can substantially contribute to advancing public-health solutions.”
To view the full press release, visit https://ibn.fm/kAb6R
About Aditxt Inc.
Aditxt is an innovation platform dedicated to discovering, developing and deploying promising innovations. Aditxt’s ecosystem of research institutions, industry partners and shareholders collaboratively drive its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. Aditxt has a diverse innovation portfolio, including Adimune(TM) Inc., which is leading the charge in developing a novel class of therapeutics for retraining the immune system to combat organ rejection, autoimmunity and allergies. Adivir(TM) Inc. focuses on enhancing national and population health and impacting public health globally. Pearsanta(TM) Inc. delivers rapid, personalized and high-quality lab testing accessible anytime, anywhere, led by its CLIA-certified and CAP-accredited clinical laboratory based in Richmond, Virginia. For more information, please visit www.Aditxt.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at http://ibn.fm/ADTX
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN